Healthcare
CSL Ltd.(CSLLY)
Live Price
Offline$18.64
-2.20% today
1Y Change
-49.86%
Window
Jun 26, 2025 → Jun 24, 2026
- Market Cap
- $43.51B
- Revenue Growth
- +4.3%
- EPS Growth
- +13.3%
- Dividend Yield
- 3.4%
Coverage: 249 bars · Jun 26, 2025 → Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
CSL Ltd. (CSLLY) is a Healthcare stock with a market cap of $43.51B and listed on OTC. The stock last traded around $18.64 and down 49.9% across the available one-year price window (Jun 26, 2025 → Jun 24, 2026). Baseline metrics include revenue growth of +4.3%, EPS growth of +13.3%, a dividend yield of 3.4%. What stands out right now is revenue +4.3%, EPS +13.3%, free cash flow +68.9% with operating margin 25.7% and ROIC 10.4%. The dividend matters to the case here, with a current yield around 3.4%. Valuation already assumes a fairly strong business story at P/E 30.1 and price/sales 2.8. Stock Foundry combines CSLLY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+4.3% vs +7.6% peer median
Operating Margin
Above sector median
+25.7% vs +19.4% peer median
P/E
Below sector median
30.1 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating story is still moving forward
Revenue is running at +4.3% and EPS at +13.3%, with operating margin around 25.7%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 3.4%, which matters if the thesis depends on income as much as growth.
Benchmark Edge
CSLLY vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CSLLY
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CSLLY Max Drawdown
-63.25%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CSLLY and SPY.
Company Overview
CSL Ltd.
OTC
CSL Limited Sponsored ADR represents shares of the Australian biotechnology company CSL Limited that are traded on American stock exchanges. CSL Limited is renowned for its focus on developing and manufacturing innovative biopharmaceutical products, especially in the fields of immunotherapy and protein-based therapies. The company's product portfolio includes a wide range of medicines used to treat bleeding disorders, immune deficiencies, and neurological disorders, serving critical medical needs globally. By issuing sponsored ADRs, CSL Limited extends its reach to U.S. investors, allowing them to access its shares without needing to purchase them directly on Australian exchanges. This ADR plays a significant role in expanding the company’s investor base, thereby increasing its capital inflows and enhancing liquidity. CSL's operations greatly impact the healthcare sector, providing advanced therapeutics that drive progress in medical science and improve patient outcomes around the world. As a leader in the biotechnology industry, CSL is committed to sustaining its growth through R&D and strategic expansion, solidifying its position as a key player in the global pharma and biotech markets.
- Leadership
- Mr. Gordon Naylor BEng (Hons), C.P.A., DipCompSc, M.B.A.
- Employees
- 29.9k
- Street Address
- 655 Elizabeth Street
- Mailing
- Melbourne, VIC, 3000
- Region
- Melbourne, VIC, Australia
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 30.1
- EV/EBITDA
- 10.7
- Price/Sales
- 2.8
- Price/Book
- 2.3
Growth
- Revenue
- +4.3%
- EPS
- +13.3%
- Free Cash Flow
- +68.9%
Profitability
- Gross Margin
- 48.6%
- Operating Margin
- 25.7%
- Net Margin
- 9.2%
- ROE
- 7.6%
- ROIC
- 10.4%
Balance Sheet
- Debt/Equity
- 0.67
- Current Ratio
- 2.57
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.